A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Monash University researchers used CRISPR or a PTPN2 inhibitor to enhance CAR T cell function against solid tumors. Blocking ...

Reviving an ancient human gene that prevents gout and fatty liver disease, scientists at Georgia State University have marked ...

The immune system faces a delicate balancing act: it must be aggressive enough to fight infections and cancer, yet restrained ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

Jayden Wilsey was the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease after federal approval in 2024.

Stem cells hold a tremendous amount of research promise. At one time, obtaining them seemed to be a nearly insurmountable challenge, until a process was invented by Gladstone Senior Investigator ...